314 related articles for article (PubMed ID: 24684593)
1. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
Beswick L; Friedman AB; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
[TBL] [Abstract][Full Text] [Related]
2. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
3. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
4. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.
Simsek M; Meijer B; Mulder CJJ; van Bodegraven AA; de Boer NKH
Ther Drug Monit; 2017 Dec; 39(6):584-588. PubMed ID: 29040228
[TBL] [Abstract][Full Text] [Related]
5. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
7. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
[TBL] [Abstract][Full Text] [Related]
8. Review article: thiopurines in inflammatory bowel disease.
Derijks LJ; Gilissen LP; Hooymans PM; Hommes DW
Aliment Pharmacol Ther; 2006 Sep; 24(5):715-29. PubMed ID: 16918876
[TBL] [Abstract][Full Text] [Related]
9. Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond.
Fong SC; Blaker PA; Arenas-Hernandez M; Marinaki AM; Sanderson JD
Biomark Med; 2015; 9(1):51-65. PubMed ID: 25605455
[TBL] [Abstract][Full Text] [Related]
10. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine therapy in inflammatory bowel disease.
Ha C; Dassopoulos T
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):575-88. PubMed ID: 20932143
[TBL] [Abstract][Full Text] [Related]
12. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
Nguyen TV; Nguyen TM; Lachaux A; Boulieu R
J Clin Pharmacol; 2013 Sep; 53(9):900-8. PubMed ID: 23856979
[TBL] [Abstract][Full Text] [Related]
14. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.
Seidman EG
Rev Gastroenterol Disord; 2003; 3 Suppl 1():S30-8. PubMed ID: 12684587
[TBL] [Abstract][Full Text] [Related]
15. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease.
Kennedy NA; Asser TL; Mountifield RE; Doogue MP; Andrews JM; Bampton PA
Intern Med J; 2013 Mar; 43(3):278-86. PubMed ID: 22946880
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Gilissen LP; Bierau J; Derijks LJ; Bos LP; Hooymans PM; van Gennip A; Stockbrügger RW; Engels LG
Aliment Pharmacol Ther; 2005 Oct; 22(7):605-11. PubMed ID: 16181300
[TBL] [Abstract][Full Text] [Related]
18. Allopurinol safely and effectively optimises thiopurine metabolites in patients with autoimmune hepatitis.
de Boer YS; van Gerven NM; de Boer NK; Mulder CJ; Bouma G; van Nieuwkerk CM
Aliment Pharmacol Ther; 2013 Mar; 37(6):640-6. PubMed ID: 23347359
[TBL] [Abstract][Full Text] [Related]
19. Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux JB; Peyrin-Biroulet L; Sparrow MP
Inflamm Bowel Dis; 2011 Jun; 17(6):1428-35. PubMed ID: 20949566
[TBL] [Abstract][Full Text] [Related]
20. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]